Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-18
2007-09-18
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S229500, C514S252100, C540S458000
Reexamination Certificate
active
11020870
ABSTRACT:
The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′- and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.
REFERENCES:
patent: 3338888 (1967-08-01), Bickel et al.
patent: 4690919 (1987-09-01), Yamane et al.
patent: 4859661 (1989-08-01), Kano et al.
patent: 4965261 (1990-10-01), Kano et al.
patent: 4983602 (1991-01-01), Yamane et al.
patent: 5547683 (1996-08-01), Yano et al.
patent: 5786349 (1998-07-01), Yamashita et al.
patent: 5981522 (1999-11-01), Yamashita et al.
patent: 6316433 (2001-11-01), Rose et al.
patent: 6486161 (2002-11-01), Fujii et al.
patent: 6566354 (2003-05-01), Rose et al.
patent: 6900204 (2005-05-01), Michaelis et al.
patent: 2003/0203903 (2003-10-01), Rose et al.
patent: 2003/0236265 (2003-12-01), Sayada
patent: 2004/0014749 (2004-01-01), Michaelis et al.
patent: 2004/0014750 (2004-01-01), Michaelis et al.
patent: 2004/0034021 (2004-02-01), Michaelis et al.
patent: 2004/0063718 (2004-04-01), Michaelis et al.
patent: 2004/0077533 (2004-04-01), Sayada
patent: 2004/0106590 (2004-06-01), Elsenstein
patent: 2005/0043298 (2005-02-01), van Duzer et al.
patent: 2005/0137189 (2005-06-01), van Duzer et al.
patent: 58-225093 (1983-12-01), None
patent: 59-231092 (1984-12-01), None
patent: 61-022090 (1986-01-01), None
patent: 62-240688 (1987-10-01), None
patent: 62-242687 (1987-10-01), None
patent: 63-035578 (1988-02-01), None
patent: 63-035579 (1988-02-01), None
patent: 63-233987 (1988-09-01), None
patent: WO97/09047 (1997-03-01), None
patent: WO 2005/020894 (2005-03-01), None
patent: WO 2005/058231 (2005-06-01), None
Bermudez et al., “Activity of KRM 1648 Alone or in Combination with Ethambutol or Clarithromycin Against Mycobacterium Avium in Beige Mouse Model of Disseminated Infection,”Antimicrobial Agents and Chemotherapy38(8):1844-1848 (1994).
Dhople, “In Vivo Susceptibility of Mycobacterium Ulcerans to KRM-1648, A New Benzoxazinorifamycin, in Comparison with Rifampicin,”Arzneimittelforschung51(6):501-505 (2001).
Dietze et al., “Safety and Bactericidal Activity of Rifalazil in Patients with Pulmonary Tuberculosis,”Antimicrobial Agents and Chemotherapy45(7):1972-1976 (2001).
Emori et al., “Evaluation of in Vivo Therapeutic Efficacy of a New Benzoxazinorifamycin, KRM-1648, in SCID Mouse Model for Disseminated Mycobacterium Avium Complex Infection,”International Journal of Antimicrobial Agents10(1):59-65 (1998).
Fujii et al., “In Vitro and In Vivo Antibacterial Activities of KRM-1648 and KRM-1657, New Rifamycin Derivatives,”Antimicrobial Agents and Chemotherapy38:1118-1122 (1994).
Gidoh et al., “Bactericidal Action at Low Doses of a New Rifamycin Derivative, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl) Benzoxazinorifamycin (KRM-1648) on Mycobacterium Leprae Inoculated into Footpads of Nude Mice,”Leprosy Review63(4):319-328 (1992).
Heep et al., “Detection of Rifabutin Resistance and Association of rpoB Mutations with Resistance to Four Rifamycin Derivatives in Helicobacter Pylori,”European Journal of Clinical Microbiology&Infectious Diseases21:143-145 (2002).
Hirata et al., “In Vitro and In Vivo Activities of the Benzoxazinorifamycin KRM-1648 Against Mycobacterium Tuberculosis,”Antimocrobial Agents and Chemotherapy39(10):2295-2303 (1995).
Hosoe et al., “Identification and Antimicrobial Activity of Urinary Metabolites of a Rifamycin Derivative in Dog,”Xenobiotica26(3):321-332 (1995).
Hosoe et al., “Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in Rats and Dogs,”Antimicrobial Agents and Chemotherapy40(12):2749-2755 (1996).
Ji et al., “How Effective is KRM-1648 in Treatment of Disseminated Mycobacterium Avium Complex Infections in Beige Mice?,”Antimicrobial Agents and Chemotherapy40(2):437-442 (1996).
Kelly et al., “Low-Dose Aerosol Infection Model for Testing Drugs for Efficacy Against Mycobacterium Tuberculosis,”Antimicrobial Agents and Chemotherapy40(12):2809-2812 (1996).
Klemens et al., “Activity of KRM-1648 in Combination with Isoniazid Against Mycobacterium Tuberculosis in a Murine Model,”Antimicrobial Agents and Chemotherapy40(2):298-301 (1996).
Kump et al., “Zur Kenntnis von Rifamycin-S. Reaktionen des chinoiden Nucleus. Modifikationen von Antibiotica, 9. (Understanding of Rifamycin S. Reactions of the quinoid nucleus. Modifications of Antibiotics.9)”Helvetica Chimica Acta56(7):2348-2377 (1973). [English Abstract].
Kuo et al., “A Comparison of the In-Vitro Sensitivity of Chlamydia Pneumoniae to Macrolides and a New Benzoxazinorifamycin, KRM-1648,”Infectious Disease and Therapy, 21:317-321 (1997).
Lenaerts et al., “Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model,”Antimicrobial Agents and Chemotherapy44(11):3167-3168 (2000).
Mae et al., “Effect of a New Rifamycin Derivative, Rifalazil, on Liver Microsomal Enzyme Induction in Rat and Dog,”Xenobiotica28(8):759-766 (1998).
Mae et al., “Isolation and Identification of Major Metabolites of Rifalazil in Mouse and Human,”Xenobiotica29:1073-1087 (1999).
Roblin et al., “In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 Against Chlamydia Trachomatis and Recent Clinical Isolates of Chlamydia Pneumoniae,”Antimicrobial Agents and Chemotherapy47:1135-1136 (2003).
Saito et al., “Therapeutic Efficacy of Benzoxazinorifamycin, KRM-1648, Against Disseminated Mycobacterium Avium Infection Induced in Rabbits,”Abstracts of the General Meeting of the American Society for Microbiology93:174 (1993). [Abstract U31].
Sano et al., “Therapeutic Effects of Benzoxazinorifamycin KRM-1648 Administered Alone or in Combination with a Half-sized Secretory Leukocyte Protease Inhibitor or the Nonsteroidal Anti-inflammatory Drug Diclofenac Sodium against Mycobacterium Avium Complex Infection in Mice,”Antimicrobial Agents and Chemotherapy43(2):360-364 (1999).
Sato et al., “Antimicrobial Activities of Benzoxazinorifamycin KRM-1648, Clarithromycin and Levofloxacin Against Intracellular Mycobacterium Avium Complex Phagocytosed by Murine Peritoneal Macrophages,”Journal of Antimicrobial Chemotherapy41(1):77-83 (1998).
Seligson et al., “A New Prodrug of Paclitaxel: Synthesis of Protaxel.”Anti-Cancer Drugs12(4):305-313 (2001).
Shimizu et al., “Effects of the Chinese Traditional Medicine Mao-bushi-saishin-to on Therapeutic Efficacy of a New Benzoxazinorifamycin, KRM-1648, Against Mycobacterium Avium Infection in Mice,”Antimicrobial Agents and Chemotherapy43(3):514-519 (1999).
Shoen et al., “Evaluation of Rifalazil in Long-term Treatment Regimens for Tuberculosis in Mice,”Antimicrobial Agents and Chemotherapy44(6):1458-1462 (2000).
Tomioka et al., “Effects of Benzoxazinorifamycin KRM-1648 on Cytokine Production at Sites of Mycobacterium Avium Complex Infection Induced in Mice,”Antimicrobial Agents and Chemotherapy41(2):357-362 (1997).
Tomioka et al., “In Vivo Antileprosy Activity of the Newly Synthesized Benzoxazinorifamycin, KRM-1648,”International Journal of Leprosy61(2):255-258 (1993).
Tomioka et al., “Intramacrophage Passage of Mycobacterium Tuberculosis and M. Avium Complex Alters the Drug Susceptibilities of the Organisms as Determined by Intracellular Susceptibility Testing using Macrophages and Type II Alveolar Epithelial Cells,ȁ
Geiss William B.
Michaelis Arthur F.
Raker Joseph
Siedlecki James M.
Stafford Douglas G.
ActivBiotics, Inc.
Clark & Elbing LLP
LandOfFree
Rifamycin analogs and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rifamycin analogs and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rifamycin analogs and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3795785